REHOVOT, Israel, July 26,
2022 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene Ltd.
(Nasdaq: EVGN) (TASE: EVGN), today announced that the first patient
was dosed in its Phase I clinical trial that is designed primarily
to evaluate the safety and tolerability of Biomica's
microbiome-based immuno-oncology drug candidate, BMC128, in
combination with immune checkpoint inhibitor (ICI) immunotherapy,
in patients with either non-small cell lung cancer (NSCLC),
melanoma or renal cell carcinoma (RCC). Bristol Myers Squibb's Opdivo® is the immune checkpoint
inhibitor in the trial.
Dr. Elran Haber, CEO of Biomica, stated: "We are very
pleased that our trial is now underway with our first patient
dosing. As the trial is open-label, we expect preliminary results
and first data point readout in early 2023, as our first patients
conclude their treatment programs. We are targeting to complete the
study in H2-2023."
About BMC128:
BMC128 is a rationally designed microbial consortium identified
and selected through a detailed functional microbiome analysis
using PRISM, a proprietary high-resolution microbiome analysis
platform powered by Evogene's MicroBoost AI
platform.
Developed as a Live Bacterial Product (LBP), BMC128 is an LBP
consortium comprised of four unique bacterial strains, natural
inhabitants of the human intestinal tract, that harbor specific
functional capabilities with the potential to enhance immunological
therapeutic responses and facilitate anti-tumor immune activity
through multiple biological processes.
Rationally-designed consortia are multi-strain products designed
to restore diversity and specific functionality to a host's
microbial community with individually selected, cultured
bacteria.
About Biomica Ltd.:
Biomica is a clinical-stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing a dedicated
Computational Predictive Biology platform (CPB), licensed from
Evogene. Biomica aims to identify and characterize disease-related
microbiome entities and to develop novel therapeutics based on
these understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more
information, please visit www.biomicamed.com.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
probability of success while reducing development time and cost.
Evogene established three unique technological engines -
MicroBoost AI, ChemPass AI and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
technological engine is focused on the discovery and
development of products based on one of the following core
components: microbes (MicroBoost AI), small molecules (ChemPass
AI), and genetic elements (GeneRator AI). Evogene uses its
technological engines to develop products through subsidiaries and
with strategic partners. Currently, Evogene's main
subsidiaries utilize the technological engines to develop human
microbiome-based therapeutics by Biomica Ltd., medical cannabis
products by Canonic Ltd., ag-chemicals by AgPlenus Ltd. and
ag-biologicals by Lavie Bio Ltd. For more information, please
visit: www.evogene.com.
Forward Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates", "targeting" or words
of similar meaning. For example, Biomica and Evogene are using
forward-looking statements in this press release when they discuss
the potential safety, tolerability and capabilities of, Biomica's
BMC-128 drug candidate, the timing of the clinical trial and the
potential success of treatment with Biomica's BMC128 in combination
with ICI immunotherapy. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, those risk factors contained in
Evogene's reports filed with the applicable securities authorities.
Evogene and its subsidiaries disclaim any obligation or commitment
to update these forward-looking statements to reflect future events
or developments or changes in expectations, estimates,
projections.
Contact:
Kenny
Green
E: evogene@egkir.com
T: +1 212 378 8040
Logo -
https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg
Logo - https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-announces-first-patient-dosed-in-its-phase-i-study-of-its-microbiome-based-immuno-oncology-drug-301593247.html
SOURCE Biomica Ltd.